Synthesis, Preclinical Characterizations and Imaging Studies of [ 18 F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent
Journal of Labelled Compounds and Radiopharmaceuticals · 2025
DOI: 10.1002/jlcr.4142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2025. Verfasst von Yu Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hubei NO.3 People's Hospital of Jianghan University, Wuhan, China. Hauptthemen laut MEDLINE: Carbonic Anhydrase IX, Carcinoma, Renal Cell, Kidney Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
The protein carbonic anhydrase IX (CAIX) is highly expressed in clear cell renal cell carcinoma (ccRCC), and its restrictive expression in healthy tissues makes CAIX an attractive diagnostic target. The purpose of this study was to synthesize and evaluate [ 18 F]AlF‐NY104, a small‐molecule CAIX‐targeting PET agent in a preclinical ccRCC model. The radiolabeling parameters for [ 18 F]AlF‐NY104 have been optimized, including the solvent volume and reaction temperature. The high‐purity product was synthesized by using an automated multifunctional module Mortenon M1, leading to nondecay‐corrected radiochemical yields over 50% ( n = 3). [ 18 F]AlF‐NY104 showed excellent tumor targeting capability and afforded high‐quality microPET/CT imaging in the OS‐RC‐2 tumor model (15.01 ± 0.76 %ID/g [mean ± SEM]). The radiation exposure from [ 18 F]AlF‐NY104 is estimated to be 4.44 mSv for adult male and female human subjects, which is well below the FDA recommended whole‐body single exposure limit of 30 mSv. Our investigation revealed that [ 18 F]AlF‐NY104 can be conveniently and efficiently radiolabeled by using an automated module. [ 18 F]AlF‐NY104 exhibited many outstanding properties, such as rapid uptake in tumor, rapid clearance through the kidney, and low uptake in most normal organs. Moreover, the high accumulation of [ 18 F]AlF‐NY104 in tumors in CAIX‐positive models offers an alternative diagnostic strategy for patients with ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hubei NO.3 People's Hospital of Jianghan University, Wuhan, China.
- Norroy Bioscience Co., LTD, Wuxi, China.
ORCID-Profile: Si Yang
Zitieren
APA
Huang, Y., Eng, W., Shao, C., Cheng, G., Qiang, C., Peng, W., Yang, S., & Liu, S. (2025). Synthesis, Preclinical Characterizations and Imaging Studies of [ 18 F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4142
Vancouver
Huang Y, Eng W, Shao C, Cheng G, Qiang C, Peng W, et al. Synthesis, Preclinical Characterizations and Imaging Studies of [ 18 F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent. Journal of Labelled Compounds and Radiopharmaceuticals. 2025. doi:10.1002/jlcr.4142
BibTeX
@article{Huang2025,
author = {Huang, Yu and Eng, Waisi and Shao, Chong and Cheng, Gaoliang and Qiang, Changwu and Peng, Wei and Yang, Si and Liu, Shiguo},
title = {Synthesis, Preclinical Characterizations and Imaging Studies of [ 18 F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2025},
doi = {10.1002/jlcr.4142}
}
EUVIMED